Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update

WEST BRIDGEWATER, Mass., Nov. 12 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that total revenue for the three months ended September 30, 2007 was $138,052 compared to $92,211 for the same period in 2006, an increase of approximately 50%. Revenue from the sale of PCT products and services was $106,787 for the quarter as compared to $92,211 for the same period in the prior year. This increase in revenue from PCT products and services was primarily the result of a record number of installations of the Company's PCT Sample Preparation System ("PCT System") -- the total number of PCT Systems installed during the quarter was eight as compared to three in the same period in 2006. Also contributing to this increase in revenue was an increase in the number of PULSE Tubes sold, revenue from PCT Systems under lease, and the recognition of extended service contract revenue. The Company also recorded $31,265 of grant revenue during the third quarter of 2007. During the same period in 2006, no grant revenue was recorded.

The Company reported total revenue of $471,799 for the nine months ended September 30, 2007 as compared to $174,409 for the nine months ended September 30, 2006, an increase of approximately 171%. Revenue from the sale of PCT products and services was $281,084 for the nine months ended September 30, 2007 as compared to $174,409 for the same period in the prior year. This increase in revenue from PCT products and services was primarily the result of a total of thirteen installations of PCT Systems (sale of eleven and the lease of two) in the first nine months of 2007 versus five in the first nine months of 2006. Also contributing to this increase in revenue was a significant increase in the number of PULSE Tubes sold, revenue from PCT Systems under lease, and the recognition of extended service contract revenue. The Company also recorded $190,715 of grant revenue during the first nine months of 2007. During the same period in 2006, no grant revenue was recorded.

Net loss for the quarter ended September 30, 2007 was $(1,095,978) or $(0.53) per share, basic and diluted, compared to a net loss of $(630,539) or $(0.26) per share, basic and diluted, for the same period in 2006. Net loss for the nine months ended September 30, 2007 was $(183,145) or $(0.09) per share, basic and diluted, compared to a net loss of $(1,754,834) or $(0.72) per share, basic and diluted, for the same nine month period in 2006. This significant reduction in net loss was due entirely to the gain of approximately $2,000,000 from the sale of our remaining shares of Panacos Pharmaceuticals common stock and from the recognition of an approximately $1,156,000 gain on the sale of net assets related to discontinued operations of Source Scientific, LLC. As of September 30, 2007, the Company had cash and cash equivalents of approximately $6.0 million, as compared to approximately $5.3 million on December 31, 2006.

Edward H. Myles, Senior Vice President of Finance and CFO commented: "During the third quarter of 2007, we carefully deployed our capital resources towards the continued development and commercialization of PCT. To this end, our cash burn and operating loss were in line with our internal expectations as we continued to make progress building market awareness while concomitantly driving the installed base of instruments."

Mr. Myles continued: "We are quite pleased that we installed eight PCT Systems during the third quarter, more than double the number that we installed in the prior year period. Although total revenue increased significantly, revenue from PCT products and services did not grow at the same rate for three primary reasons: (1) four of eight PCT Systems sold used the Barocycler NEP2320 instrument from the initial prototype run of this unit -- these PCT Systems have a list price of approximately half of the Barocycler NEP3229-based PCT Sample Preparation System; (2) we accepted the return, and issued a credit, for the full price (approximately $30,000) of a Barocycler NEP3229 PCT System that was sold last year because the sample throughput did not ultimately meet the needs of that particular researcher; and (3) two of the eight installations in the quarter were completed under lease/rental agreements rather than sales, whereby revenue will be recorded over the life of the specific agreement."

Richard T. Schumacher, Founder, President, and CEO of Pressure BioSciences, Inc. said: "We are very pleased with the significant increase in the number of PCT Systems installed during the first nine months of 2007, as compared to the same period in 2006. This increase gives us reason for continued optimism since it was achieved with just two sales people for the nine month period and with very limited availability of the new NEP2320 instrument (units sold were from an initial prototype run of eleven instruments, which were expected to be used exclusively for demonstration and collaboration purposes). Furthermore, we believe that our business plan is beginning to be validated, as growth in our installed base of PCT Systems has begun to result in the realization of recurring revenue -- such as PULSE Tube sales and extended service contracts."

Mr. Schumacher continued: "There were a number of additional achievements during the third quarter, including: (1) the hiring of four additional sales directors (and one more in Q4), bringing our total number on staff to seven seasoned, technical sales directors; (2) presentations and publications by several independent, eminent scientists describing their successful use of PCT in the areas of agriculture, microbiology, and human disease; (3) confirmation of the use of the NEP2320 PCT System as a highly successful demonstration tool for our sales team; and (4) continued expansion of our successful collaboration programs with existing and new researchers throughout the US."

Mr. Schumacher concluded: "We continue to believe that we have developed the 'best-in-class' sample preparation system available today, one that we believe offers significant advantages in a number of key areas -- including safety, speed, versatility, reproducibility, and quality -- to the estimated 390,000 scientists worldwide who extract DNA, RNA, proteins, and small molecules in their research studies. Combined with a new sales team of seven ambitious and experienced personnel, strong collaborations, and emerging market penetration, we believe that we are well poised to finish the year strong and to enter 2008 with our resources squarely focused on continuing and expanding our commercialization efforts."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called pressure cycling technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.

Financial Teleconference and Web-cast

As announced on November 8, 2007, the Company will host a teleconference at 4:30 pm EST on Monday November 12, 2007 to discuss its third quarter financial results and to provide a business update.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward looking statements include statements regarding the Company's expectations for the remainder of 2007 and 2008, including the continued expansion of the Company's commercialization efforts, the anticipated quality and benefits of the Company's products, and the potential use of PCT in agriculture, microbiology, and human disease; beliefs regarding the validation of the Company's business plan due to Company's growing installed base of PCT Systems; and the Company's estimate of the number of scientists extracting DNA, RNA, proteins, and small molecules. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: possible difficulties or delays in the implementation of the Company's strategies that may adversely affect the Company's continued commercialization of its PCT Sample Preparation System; the Company's financial results for the three and nine months ended September 30, 2007 may not necessarily be indicative of future results as future revenues may not meet expectations due to the possible failure of the Company's products to achieve commercial acceptance, changes in customers needs and technological innovations, and expenses that may be higher than anticipated due to unforeseen cost increases; if the Company's expenses are higher than anticipated or if the Company's revenues do not increase, the Company may not have sufficient cash to support its planned activities and the Company may be unable to obtain financing on acceptable terms; the Company's new external sales force may not be successful in selling the Company's PCT product line; and the Company may be unable to develop new PCT-related products that achieve commercial acceptance or the status of "best-in-class" sample preparation method. Additional risks and uncertainties that could cause actual results to differ materially from those indicated by these forward- looking statements are discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

    Visit us at our website http://www.pressurebiosciences.com



    Consolidated Balance Sheets (Unaudited)

                                              September 30,      December 31,
                  ASSETS                          2007               2006

    CURRENT ASSETS
       Cash and cash equivalents                $6,005,462         $5,335,282
       Accounts receivable                          75,142             37,495
       Inventories                                 238,109             19,658
       Prepaid income taxes                         56,863             38,687
       Income tax receivable                        23,494            710,013
       Prepaid expenses, deposits, and other
        current assets                             583,418            246,776
       Investments in marketable securities              -          2,060,875

       Total current assets                      6,982,488          8,448,786

    PROPERTY AND EQUIPMENT, NET                    233,773            207,696

    OTHER ASSETS
       Intangible assets, net                      340,448            376,922
       Assets of discontinued operation                  -          1,420,996
       Total other assets                          340,448          1,797,918

       TOTAL ASSETS                             $7,556,709        $10,454,400

      LIABILITIES AND STOCKHOLDERS' EQUITY

    CURRENT LIABILITIES
       Accounts payable                           $260,859           $174,289
       Accrued employee compensation               280,717            242,497
       Other accrued expenses                      143,528            150,978
       Income taxes payable                         43,339             45,962
       Deferred taxes                                    -            669,520
       Deferred revenue                             20,814              4,099

       Total current liabilities                   749,257          1,287,345

    LONG TERM LIABILITIES
       Deferred revenue                              7,568              9,126
       Liabilities of discontinued operation             -          1,042,493
       Total long term liabilities                   7,568          1,051,619

       TOTAL LIABILITIES                           756,825          2,338,964

    COMMITMENTS

    STOCKHOLDERS' EQUITY
       Common stock, $.01 par value;
        20,000,000 shares authorized;
        2,065,425 shares issued and
        outstanding                                 20,654             20,654
       Additional paid-in capital                5,600,110          5,347,641
       Accumulated other comprehensive income            -          1,384,876
       Retained earnings                         1,179,120          1,362,265

       Total stockholders' equity                6,799,884          8,115,436

       TOTAL LIABILITIES AND
        STOCKHOLDERS' EQUITY                    $7,556,709        $10,454,400



    Consolidated Statements of Operations

                                    For the Three Months  For the Nine Months
                                            Ended                Ended
                                        September 30,        September 30,
                                     2007      2006        2007        2006
    REVENUE:
      PCT products, services,
       other                       $106,787    $92,211    $281,084    $174,409
      Grant revenue                   31,26          -     190,715           -
        Total revenue               138,052     92,211     471,799     174,409

    COSTS AND EXPENSES:
      Cost of PCT products and
       services                      42,276     90,037     131,558     188,688
      Research and development      519,303    324,525   1,518,851     984,844
      Selling and marketing         379,448    127,419     986,801     322,803
      General and administrative    578,238    380,065   1,683,782   1,665,172
        Total operating costs and
         expenses                 1,519,265    922,046   4,320,992   3,161,507

        Operating loss from
         continuing operations   (1,381,213)  (829,835) (3,849,193) (2,987,098)

    OTHER INCOME:
      Realized gain on securities
       available for sale                 -          -   2,028,720     517,938
      Interest income                75,732     88,190     227,816     305,982
        Total other income           75,732     88,190   2,256,536     823,920
        Loss from continuing
         operations before income
         taxes                   (1,305,481)  (741,645) (1,592,657) (2,163,178)
        Income tax benefit from
         continuing operations      209,503    111,106     253,539     408,344
        Loss from continuing
         operations              (1,095,978)  (630,539) (1,339,118) (1,754,834)


    DISCONTINUED OPERATIONS:
      Gain on sale of net assets
       related to discontinued
       operations (net of income
       tax of $218,060)                   -          -   1,155,973           -

      Net loss                  $(1,095,978) $(630,539)  $(183,145)$(1,754,834)

      Loss per share from
       continuing operations
       - basic and diluted           $(0.53)    $(0.26)     $(0.65)     $(0.72)
      Income per share from
       discontinued operations
       - basic and diluted                -          -        0.56           -
      Net loss per share
       - basic and diluted           $(0.53)    $(0.26)     $(0.09)     $(0.72)

      Weighted average number of
       shares used to calculate
       income (loss) per share
       - basic                    2,065,425  2,422,675   2,065,425   2,424,351


     Investor Contacts:
     Richard T. Schumacher, President & CEO
     Edward H. Myles, Senior Vice President of Finance & CFO
     Pressure BioSciences, Inc.
     (T) 508-580-1818

SOURCE Pressure BioSciences, Inc.